Intro: Atrial fibrillation (AF) is the most frequently diagnosed arrhythmia in practice. Current guidelines on management of AF suggest that patients should be treated with antiarrhythmic drugs (AAD) as first-line therapy, our meta-analysis aims to assess the benefit of using of Cryoablation as a first line therapy for people with atrial fibrillation. Methods: We conducted an electronic search using Medline, Embase, CINAHL and google scholar along with other clinical trial registries. Results: 2 studies out of 9,244 studies fit our eligibility criteria. A total of 521 subjects were included in both studies and 4 distinct meta-analyses were performed. In terms of recurrence CA was superior to AAD with a RR of 0.6. For serious adverse events CA was also superior to AAD with a RR of 0.66 and for treatment related SAE the results were insignificant. Conclusion: CA proved to be superior in terms of recurrence and adverse effects versus AAD.